目的：探讨血清甲状腺球蛋白抗体（ TgAb）在评价分化型甲状腺癌（ differentiated thyroid carcinoma， DTC）转移术后131 I治疗疗效中的作用。方法以我院肿瘤科收治的50例术后病理检查证实的DTC患者为观察对象，根据经131I治疗的效果将患者分为有效组（34例）和无效组（16例），对比分析2组不同时间点血清TgAb水平。结果131I治疗前，2组血清TgAb水平差异无统计学意义（P＞0．05）。131I治疗1年后，有效组血清TgAb水平显著降低，且明显低于无效组（P＜0．05）。有效组治疗前、首次131I治疗后6个月、首次131I治疗后12个月血清TgAb水平对比差异有统计学意义（ P＜0．05），患者治疗后6个月及12个月TgAb水平均明显低于治疗前（ P＜0．05），且治疗后12个月TgAb水平明显低于治疗后6个月（P＜0．05）。结论分化型甲状腺癌术后131I治疗患者测定血清TgAb有助于评价其治疗效果和预后的改善情况。%Objective To discuss the clinical value of serum thyroglobulin antibody ( TgAb) for evaluating the effi-cacy of 131 I treatment after differentiated thyroid carcinoma ( DTC) .Methods A total of 50 DTC patients who were ad-mitted into our department of oncology and pathologically diagnosed were chosen.They were divided into an effective group (n=34) and an ineffective group (n=16) according to the efficacy of 131I treatment.Then, both groups were compared for serum TgAb level at different time points.Results Before 131 I treatment, no statistical difference was found as to serum TgAb level between the two groups (P>0.05).One year after 131I treatment, the effective group pro-duced remarkably reduced levels of serum TgAb than the ineffective group (P<0.05).The levels of serum TgAb in the effective group were markedly different before treatment, 6 months after treatment and 12 months after treatment( P<0.05), where the amounts of serum TgAb 6 months and 12 months after treatment were obviously lower than that before treatment ( P<0.05) and the amount of serum TgAb 12 months after treatment were obviously lower than that 6 months after treatment (P<0.05).Conclusion Determination of serum TgAb level is useful to evaluate the efficacy and prog-nosis of DTC patients after 131 I treatment.
展开▼
